Pharmaceutical innovation in healthcare is a multifaceted process involving numerous private and public stakeholders. New blockbuster drugs, curative therapies, and additional uses for existing medications all represent innovation and are often cited as reasons to seek care and treatment in the United States. But this doesn’t come without a price. The healthcare sector continues to see high prices and soaring costs on top of rising disease burden and inequitable outcomes across populations.
This gathering will examine the trade-offs inherent in focusing on certain areas of innovation while sidelining others. Key topics include determining who sets prices, who really receives the benefit of pharmaceutical innovation, and ultimately, for whom we are innovating. Our goal is to initiate a meaningful dialogue that re-examines our highest aspirations and opportunities in US healthcare.
As the 2023 UNC Business of Healthcare Conference approaches, this overview provides a brief introduction to the topic, “What’s Driving Healthcare Prices?”. The upcoming conference panels will further delve into topics pertinent to healthcare pricing.
As payments from the National Opioid Settlement and other opioid-related lawsuits are distributed to local governments across the country, the question many communities are asking is, ‘How should we spend the funds?’ This commentary highlights how states and local communities are approaching the challenge and how local context and community dialogue should be prioritized during decision-making processes.
COVID-19 created havoc for direct care workers in home healthcare and childcare. As the crisis continues, our experts look at what caused historic staffing shortages in direct care and changes that could provide solutions.